Another interesting gene delivery approach using mRNA was done by Gan et al. Although the phase I clinical trial was not specifically conducted in PAD-related patients, intradermal administration of modified mRNA encoding VEGF-A165 in men with type 2 diabetes mellitus could induce VEGF-A protein levels and skin blood flow 123. The gene discussed is VEGFA; the disease is peripheral arterial disease.